Titre du document / Document title

In vitro evaluation of carbamazepine 200 MG : tablets

Auteur(s) / Author(s)

KIBWAGE I. O. ; NGUYO M. ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

Univ. Nairobi, coll. health sci., dep. pharmacy, Nairoby, KENYA

Résumé / Abstract

A comparative in-vitro performance of carbamazepine 200 mg tablet products available on the Kenyan market was evaluated. The products which include the innovator product, Tegretol, have similar quality consonant with pharmacopoeal specifications. A batch of one of the products had a carbamazepine content of 106.6% label claim which was outside the upper limits of 105%. One product packaged in multiple-unit containers of a 1000, had an unacceptable high friability of 6.82% loss in weight. All products had good dissolution profiles and released at least 70% of the dose within 45 minutes. Drug dissolution from tablets was found to vary between batches for one product. At each sampling time, most generics had wide variations in amount of dissolved drug

Revue / Journal Title

East African medical journal   ISSN 0012-835X   CODEN EAMJAV 

Source / Source

1993, vol. 70, n^o8, pp. 512-514 (8 ref.)

Langue / Language

Anglais

Editeur / Publisher

Kenya Medical Association, Nairobi, KENYA  (1932) (Revue)

Mots-clés anglais / English Keywords

Chemotherapy ; Treatment ; Quality control ; Commercial form ; Indicator ; Friability ; Dissolution ; Tablet ; Kenya ; Evaluation ; In vitro ; Tricyclic compound ; Africa ;

Mots-clés français / French Keywords

Carbamazépine ; Chimiothérapie ; Traitement ; Contrôle qualité ; Forme commerciale ; Indicateur ; Friabilité ; Dissolution ; Comprimé ; Kenya ; Evaluation ; In vitro ; Composé tricyclique ; Afrique ;

Mots-clés espagnols / Spanish Keywords

Quimioterapia ; Tratamiento ; Control calidad ; Forma comercial ; Indicador ; Friabilidad ; Disolución ; Tableta ; Kenya ; Evaluación ; In vitro ; Compuesto tricíclico ; Africa ;

Localisation / Location

INIST-CNRS, Cote INIST : 17259, 35400002386911.0110